Summary
• Allurion Technologies Inc. (ALUR) shares dropped 10% to $1.13 amidst broader market pressures.
• A peer-reviewed study on the Allurion Smart Capsule’s weight loss effectiveness fails to boost the stock amid ongoing market volatility.
• Analysts maintain a “Buy” rating with a price target of $2.50, despite the stock’s significant year-to-date decline of 85.6%.
Allurion Technologies Inc. (NYSE: ALUR) is trading at $1.13, down 10% from yesterday’s close. This decline reflects a sharp sell-off during the intraday session, driven by ongoing market pressures without a defined catalyst.
Peer-Reviewed Study Released
Despite the current downturn, the company recently announced a peer-reviewed publication demonstrating the effectiveness of the Allurion Smart Capsule in combination with lifestyle interventions for weight loss. This study, published in a reputable journal, seeks to validate the weight loss benefits that may enhance the attractiveness of Allurion’s offerings. However, the impact of this announcement appears subdued in today’s turbulent market environment, failing to provide upward momentum for the stock.
Recent Developments
Allurion Technologies has made headlines with several significant announcements over the past few days. On November 18, the company revealed a strategic distribution partnership with ProSurg Medical in Brazil, aimed at enhancing its market presence in the bariatric and obesity care sectors. Earlier, on November 12, Allurion reported its third-quarter financial results, including various FDA milestones. However, there are no major releases in the last 24 hours that could be contributing to today’s notable price drop.
Analyst Insights
Currently, the stock holds a “Buy” rating from analysts, with Chardan Capital recently maintaining a price target of $2.50. This indicates that while analysts remain optimistic about the company’s long-term potential, the short-term price movements could be influenced by market volatility and investor sentiment.
Market Data Snapshot
Allurion’s current price of $1.13 reflects its continued struggles, with a year-to-date performance of -85.6% and a staggering annual decline of -91%. The stock has recently displayed a Relative Strength Index (RSI) of 31.14, suggesting that it may be approaching oversold levels, although further downside could still be in play given the current trends. The stock’s average trading volume over the past 10 days stands at 100,327, significantly lower than its three-month average volume of 166,471, indicating a lack of robust trading interest amid today’s sell-off.
With shares down significantly amid routine trading, investors continue to keep a close watch on the company’s future performance and upcoming strategic decisions that may aid in reversing its current downward trajectory.